On July 16, Boston Scientific rose 3.43% in regular trading, trading at $45.33 USD/share, with turnover of $89.52 million. The stock advanced alongside a broad rally across the Health Care Equipment sector, with Abbott Laboratories surging over 11% and leading gains industrywide.

Within the Health Care Equipment sector, the overall sector showed strong momentum. Among individual stocks, Abbott Laboratories up 11.65%, Stryker up 5.15%, Medtronic up 4.14%, Intuitive Surgical up 3.42%, IDEXX Laboratories up 3.33%. Boston Scientific's advance came despite Truist on the same day trimming its price target slightly to $62 from $64 while maintaining its Buy rating. The FactSet consensus mean target now stands at $71.36, still well above the current trading level.

The rebound follows a period of significant analyst target price reductions since late April, with firms including Jefferies, RBC, Needham, Piper Sandler, and BofA Securities cutting targets by 25%-35% on average amid headwinds from the Watchman device and a company-issued guidance reset. Management has maintained full-year organic revenue growth guidance of 6.5% to 8%, with Q2 expected as the trough quarter. The next earnings report is scheduled for July 29.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)